My name is Angelica Loskog, I am a Professor of Immunotherapy at Uppsala University in Sweden. Since more than 20 years, I have focused my  research to develop cancer immunotherapeutics based on cell- and gene therapy. Cancer is a devastating disease and it is my life goal to make a difference for cancer patients in Sweden and world wide. Together with my colleagues and coworkers, I have initiated multiple clinical trials using immunostimulatory gene therapy beginning in Sweden back in 2006 and now also internationally via Lokon Pharma, a biotech company based on my research from Uppsala University. I have also introduced CAR T cell therapy in Sweden since 2014.  I am grateful for the opportunity to explore my ideas and knowledge  about immunology, gene technology and early stage clinical trials so I can add my pieces to the gigantic cancer puzzle.  I created this website for all of you out there that want more information about what I do, if there are clinical trials available where you live and how to get in contact with our clinicians. I apologize I cannot answer all of you personally. I hope you will find the information herein useful.

Hang in there and fight cancer!




2002 Doctor of philosophy, PhD, in Clinical Immunology/Medical Sciences, Uppsala University, Uppsala, Sweden.

2003-2004 Postdoctoral associate, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX

2009-2010 Vice Head of Department and Head of division, Div of Clinical Immunology, Dept of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden.

2014-present: Professor of immunotherapy, Dept of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

2012-present: CEO at Lokon Pharma AB, Uppsala, Sweden.

2012-present: Scientific advisor/alternate board member  at venture cap NEXTTOBE AB, Uppsala, Sweden, which includes board assignments in several of their portfolio companies such as Repos Pharma AB, Vivolux AB, Bioimics AB, Tanea Medical AB, Aros Biotech AB and previously Chemilia AB (2014) and Hansa Biopharma AB (Publ) (2016-2019).

Let's fight cancer!


Selected Media


Saellström S, Sadeghi A, Eriksson E, Segall T, Dimopoulou M, Korsgren O, Loskog A, Tötterman T, Hemminki A, Rönnberg H. Adenoviral CD40 ligand immunotherapy in 32 canine malignant melanomas – long-term follow up. Front Vet Sci. 2021, in press.

 Mansoori S, Fryknäs M, Alvfors C, Loskog A, Larsson R, Nygren P. A phase 2a clinical study on the safety and efficacy of individualized mebendazole in patients with advanced gastrointestinal cancer. Sci Rep, 2021. 11:8981.

 Labani-Motlagh A, Naseri S, Wenthe J, Eriksson E, Loskog A. Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes. Mol Ther Oncolytics. 2021. 20:508-518.

 Wenthe J, Naseri S, Labani Mothlagh A, Enblad G, Wikström KI, Eriksson E, Loskog A, Lövgren T. Boosting CAR T cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy. Cancer Immunol Immunother. 2021. Epub ahead of print.

 Irenaeus S, Hellström V, Wenthe J, Krause J, Sundin A, Ahlström H, Tufveson G, Tötterman TH, Loskog A, Ullenhag G. Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors. Cancer Gene Ther. 2020. Epub ahead of print.

 Andersson CR, Selvin T, Blom K, Rubin J, Berglund M, Jarvius M, Lenhammar L, Parrow V, Loskog A, Fryknäs M, Nygren P, Larsson R. Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway. Sci Rep. 2020. 10:13124.

 Labani-Motlagh A, Ashja-Mahdavi M, Loskog A. The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses. Front Immunol. 2020. 11:940.

 Wenthe J, Naseri S, Hellström A-C, Jernberg Wiklund H, Eriksson E, Loskog A. Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40. Cancer Gene Ther. 2020. 27:948-959.

 Rowinsky EK, Paner A, Berdeja JG, Venugopal P, Porkka K, Gullbo J, Linder S, Loskog A, Richardson PG, Landgren O. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. New Invest Drugs, 2020. 38:1448-1453.

 Schitza A, Irenaeus S, Ortiz-Nieto F, Loskog A, Tötterman TH, Sundin A, Ullenhag GJ, Ahlström H. Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to assess response to AdCD40L treatment in metastatic melanoma patients. Sci Rep. 2019. 9:18069.

 Blom K, Rubin J, Berglund M, Jarvius M, Lenhammar L, Parrow V, Andersson C, Loskog A, Fryknäs M, Nygren P, Larsson R. Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1b inhibition. BMC Res Notes. 2019. 12:234.

 Amini R-M, Enblad G, Hollander P, Laszlo S, Eriksson E, Ayoola Gustafsson K, Loskog A, Thörn I. Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients. BMC Cancer. 2019. 19:216.

 Eriksson E, Milenova I, Wenthe J, Moreno R, Alemany R, Loskog A. IL-6 signaling blockade during CD40-mediated immune activation favors anti-tumor factors by reducing TGF-beta, collagen type I and PD-L1/PD1. J Immunol. 2019. 202:787-798.

 Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini R-M, Wikstrom KI, Essand M, Savoldo B, Hallböök H, Höglund M, Dotti G, Brenner MK, Hagberg H, Loskog A. A Phase I/IIa trial using CD19-targeted third generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018. 24:6185-6194.

 Rubin J, Mansoori S, Blom K, Berglund M, Lenhammar L, Andersson C, Loskog A, Fryknäs M, Nygren P, Larsson R. Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing. Oncotarget. 2018. 9:30805-30813.

 Hoffman JM, Schubert ML, Wang L, Hückelhoven A, Sellner L, Stock S, Schmitt A, Kleist C, Gern U, Loskog A, Wuchter P, Hofmann S, Ho AD, Müller-Tidow C, Dreger P Schmitt M. Differences in expansion potential of naïve chimeric antigen receptor T cells from healthy donors and untreated chronic lymphocytic leukemia patients. Front Immunol. 2018. 8:1956.

 Hollander, P., Rostgaard, K., Smedby, K.E., Molin, D., Loskog, A., de Nully Brown, P., Enblad, G., Amini, R-M., Hjalgrim, H., Glimelius, I. An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome. Eur J Haematol. 2018. 100:88-97.

 Ireaneus S, Schiza A, Mangsbo S, Wenthe J, Eriksson E, Krause J, Sundin A, Ahlström H, Tötterman TH, Loskog A, Ullenhag GJ. Local radiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients. Oncotarget. 2017. 8:78573-78587.

 Eriksson E, Milenova I, Wenthe J, Ståhle M, Leja-Jarblad J, Ullenhag G, Dimberg A, Moreno R, Alemany R, Loskog A. Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. Clin Cancer Res. 2017. 23:5846-5857.

 Schiza A, Wenthe J, Mangsbo S, Eriksson E, Nilsson A, Tötterman TH, Loskog A, Ullenhag G. Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients. J Transl Med. 2017, 15:79.

 Blom K, Senkowski W, Jarvius M, Berglund M, Rubin J, Lenhammar L, Parrow V, Andersson C, Loskog A, Fryknäs M, Nygren P, Larsson R. The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation. Immunopharmacol Immunotoxicol. 2017. 39:199-210.

 Kaartinen T, Luostarinen A, Maliniemi P, Keto J, Arvas M,  Belt H, Koponen J, Loskog A, Mustjoki S, Porkka K, Ylä-Herttuala S, Korhonen M. Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion. Cytotherapy 2017. 19:1130.

 Eriksson E, Moreno R, Milenova I, Liljenfeldt L, Dieterich L, Christiansson L, Karlsson H, Ullenhag G, Mangsbo S, Dimberg A, Alemany R, Loskog A. Activation of myeloid- and endothelial cells by CD40L immunotherapy supports T-cell expansion and migration into the tumor microenvironment. Gene Therapy. 2017, 24:92-103.

 Yu D, Leja-Jarblad J, Loskog A, Hellman A, Giandomenico V, Öberg K, Essand M. Preclinical evaluation of AdVince, an oncolytic adenovirus adapted for treatment of liver metastases from neuroendocrine cancer. Neuroendocrinology. 2017. 105:54-66.

 Söderlund, S., Christiansson, L., Persson, I., Koskenvesa, P., Richter, J., Hjort-Hansen, H., Simonsson, B., Mustjoki, S., Olsson-Strömberg, U., Loskog, A. Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. Leuk Res. 2016, 50:95-103.

 Eriksson, E., Wenthe, J., Irenaeus, S., Loskog, A., Ullenhag, G. Gemcitabine reduces MDSCs, Tregs and TGFb-1 while restoring the Teff:Treg ratio in patients with pancreatic cancer. J Transl Med. 2016, 14:282.

 Loskog, A., Maleka, A., Mangsbo, S., Svensson, E., Lundberg, C., Nilsson, A., Krause, J., Agnarsdóttir, M., Sundin, A., Ahlström, H., Tötterman, T.H., Ullenhag, G. Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. Br J Cancer. 2016, 114:872-880.

 Karlsson, H., Svensson, E., Gigg, C., Jarvius, M., Ohlsson Stromberg, U., Savoldo, B., Dotti, G., Loskog, A. Evaluation of intracellular signaling downstream chimeric antigen receptors. Plos One. 2015, 10:e0144787.

 Loskog A. Immunostimualtory gene therapy using oncolytic viruses as vehicles. Viruses. 2015, 7:5780-5791.

 Enblad, G. Karlsson, H., Loskog, S.I. Angelica. CAR T cell therapy – the role of physical barriers and immunosuppression in lymphoma. Human Gene Ther. 2015, 26:498-505.

 Rodriguez-Garcia A, Svensson E, Gil-Hoyos R, Fajardo C, Rojas L-A, Arias-Badia M, Loskog A, and Alemany R. Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity. Gene Ther. 2015, 22:596-601.

 Christiansson, L., Söderlund, S., Mangsbo, S., Hjorth-Hansen, H., Höglund, M., Markevärn, B., Richter, J., Stenke, L., Mustjoki, S., Loskog, A., Olsson-Strömberg, U. The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses. Mol Cancer Ther. 2015, 14:1181-1191.

 Huang, H., Langenkamp, E., Georganaki, M., Loskog, A., Fredlund Fuchs, P., Dieterich, L.C., Kreuger, J., Dimberg, A. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kB-induced endothelial activation. FASEB J. 2015, 29:227-238.

 Burman, J., Svensson, E., Fransson, M., Loskog, SIA, Zetterberg, H., Raininko, R., Svenningsson, A., Fagius, J., Mangsbo, M.S. The cerebrospinal fluid cytokine signature of multiple sclerosis: a homogenous response that does not conform to the Th1/Th2/Th17 convention. J Neuroimmunol. 2014, 277(1-2):153-159.

 Christiansson, L., Mustjoki, S., Simonsson, B., Olsson-Strömberg, U., Loskog, A.S.I., Mangsbo, S. The use of multiplex platforms for absolute and relative protein quantification of clinical material. EuPA Open Proteomics. 2014, 3:37-47.

 Fransson, M., Piras, E., Wang, H., Burman, J., Rasmusson Duprez, I., Harris, R.A., LeBlanc, K., Magnusson, P.U., Brittebo, E., Loskog, A.S.I. Intranasal delivery of CNS-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis. Immunology. 2014, 142:431-441.

 Burman J, Zetterberg H, Fransson M, Loskog ASI, Raininko R, Fagius J. Assessing tissue damage in multiple sclerosis: a biomarker approach. Acta Neurol Scand. 2014, 130:81-89.

 Sandin, L.C., Eriksson, F., Ellmark, P., Loskog, A.S.I., Tötterman, T.H., Mangsbo, S. Local CTLA-4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. OncoImmunol. 2014, 3:e27614.

 Liljenfeldt, L., Dieterich, L., Dimberg, A., Mangsbo, S., Loskog, A.S. CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes. Cancer Gene Ther. 2014, 21:95-102.

 Liljenfeldt, L., Gkirtzimanaki, K., Vyrla, D., Svensson, E., Loskog, A., Eliopoulos, A. Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand. Cancer Immunol Immunother. 2014, 63:273-282.

 Westberg, S., Sadeghi, A., Svensson, E., Segall, T., Dimopoulou, M., Korsgren, O., Hemminki, A., Loskog, S.I.A., Tötterman, T.H., von Euler, H. Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma. J Immunother. 2013, 36:350-358.

 Karlsson, H.S.C., Lindqvist, C.A., Fransson, M., Paul Wetterberg, G., Nilsson, B., Essand., Nilsson, K., Frisk, P., Jernberg-Wiklund, H., Loskog, S.I.A. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy. Cancer Gene Ther. 2013, 20:386-393.

 Burman, J., Fransson, M., Tötterman, TH., Fagius, J., Mangsbo, SM., Loskog, ASI. T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis. Immunology. 2013, 140:211-219.

 Christiansson, L., Söderlund, S., Svensson, E., Mustjoki, S., Bengtsson, M., Simonsson, B., Strömberg-Olsson, U., Loskog, A.S. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in sokal high risk chronic myeloid leukemia. PLoS One. 2013, 8:e55818.

 Essand, M., Loskog, A.S.I. Genetically engineered T cells for the treatment of cancer. J Intern Med. 2013, 273:166-181.

 Dieterich, L.C., Schiller, P., Huang, H., Wawrousek, E.F., Loskog, A., Wanders, A., Moons, L., Dimberg, A. aB-crystallin regulates expansion of CD11b+Gr-1+ immature myeloid cells during tumor progression. FASEB J. 2013, 27:151-162.

 Ullenhag, G., Loskog, S.I.A. AdCD40L – crossing the valley of death. Int Rev Immunol. 2012, 4:289-298.

 Fransson, M., Piras, E., Burman, J., Nilsson, B., Essand, M., BinFeng, L., Harris, R.A., Magnusson, P.U., Brittebo, E., Loskog, A.S.I. CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J Neuroinflammation. 2012, 9:112.

 Lindqvist, C.A. and Loskog, S.I.A. T regulatory cells in B cell malignancy – tumor support or kiss of death? Immunology. 2012, 135:255-260.

 Diaconu, I., Cerullo, V., Hirvinen, M.L., Escutenaire, S., Ugolini, M., Pesonen, S.K., Bramante, S., Parviainen, S., Kanerva, A., Loskog, A., Eliopoulos, A., Pesonen, S., Hemminki, A. Immune response is an important aspect of the anti-tumor effect of an oncolytic adenovirus coding for CD40L. Cancer Res. 2012, 72:2327-2338.

 Dias JD., Hemminki, O., Diaconu, I., Hirvinen, M., Bonetti, Guse, K., Escuteniare, S., Kanerva, A., Pesonen, S., Loskog, A., Cerullo, V., and Hemminki, A. Targeted cancer immunotherapy with a oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.  Gene Ther. 2012, 19:988-998.

 Lindqvist, C., Christiansson, L., Thörn, I., Mangsbo, S., Wetterberg, G., Sundström, C., Tötterman, T.H., Simonsson, B., Enblad, G., Frisk, P., Olsson-Strömberg, U., and Loskog, A. Both CD4(+) FoxP3(+) and CD4(+) FoxP3(-) T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.Immunology. 2011, 133:296-306.

 Lindqvist, C.A., Christiansson, L.H., Simonsson, B., Enblad, G., Olsson-Stromberg, U., Loskog, S.I.A. T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology. 2010, 131:371-376.

Malmström, P-U., Loskog, A., Lindqvist, C., Mangsbo, S., Fransson, M., Wanders, A., Gårdmark, T., Tötterman, T.H. AdCD40L immunogene therapy for bladder carcinoma – the first phase I/IIa trial. Clin Cancer Res. 2010, 16:3279-3287.

 Mangsbo, SM., Sandin-Gustavsson, L.C., Anger, K., Korman, A., Loskog, A., and Tötterman, T.H. Enhanced tumor eradication by combining CTLA4 or PD1 blockade with CpG therapy. J Immunother. 2010, 33:225-235.

 Fransson, M., Burman, J., Lindqvist C, Atterby, C., Fagius, J., Loskog, A. T regulatory cells lacking CD25 are increased in MS during relapse. Autoimmunity. 2010, 43:590-597.

 Mangsbo, S.M., Sanchez, J., Anger, K., Lambris, J.D., Ekdahl, K.N., Loskog, A.S., Nilsson, B., Tötterman, T.H. Complement activation by CpG in a human whole blood loop system; mechanisms and immunomodulatory effects. J Immunol. 2009, 183:6724-6732.

 Lindqvist, C., Sandin, L.C., Fransson, M., and Loskog, A. Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition. J Immunother. 2009, 32:785-792.

 Loskog, ASI., Eliopoulos AG. The Janus faces of CD40 in cancer. Semin Immunol. 2009,  21:301-307. Review.

 Vardouli, L., Lindqvist, C. Vlahou, K., Loskog, AS., and Eliopoulos, AG. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Cancer Gene Ther. 2009, 16:848-860.

 Vikman, S., Sommaggio, R. de la Torre, M., Öberg, K., Essand, M., Giandomenico, V., Loskog, A., and Totterman, T.H. Midgut carcinoid patients display increased numbers of regulatory T cells in blood with infiltration into tumor tissue. Acta Oncol. 2009. 48:391-400.

 Fransson, M., Liljenfeldt, L., Fagius, J., Tötterman, T.H., and Loskog, A. The T cell pool is anergized in patients with multiple sclerosis in remission. Immunology. 2009, 126:92-101.

 von Euler, H., Sadeghi, A., Carlsson, B., Rivera, P., Loskog, A., Segall, T., Tötterman, T.H. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother. 2008, 31:377-84

Mangsbo, S.M., Ninalga, C., Essand, M., Loskog, A., and Tötterman, T.H. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T cell immunity. J Immunother. 2008. 31:34-42.

Loskog, A., and Tötterman, T.H. Genetic engineering – a new era for cancer immunotherapy? Curr Cancer Ther Rev. 2007, 3:194-198. Review.

 Loskog, A., and Tötterman, T.H. CD40L – a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets. 2007, 7:23-28. Review.

 Loskog, A., Ninalga, C., Paul-Wetterberg, G., de la Torre, M., Malmström, P-U., and Tötterman, T.H. Human bladder carcinoma is dominated by T regulatory cells and Th1-inhibitory cytokines. J Urol. 2007, 177:353-358.

 Loskog, A.,Giandomenico, V., Rossig, C., Pule, M., Rooney, C.M., Dotti, G., and Brenner, M.K. Addition of the CD28 signaling domain to chimeric T cell receptors enhances CTL activation and resistance to T regulatory cells. Leukemia. 2006, 20:1819-1828.

 Dzojic, H., Loskog, A., Totterman, T.H., Essand,  M.E. Adenovirus-mediated CD40 Ligand therapy induces tumor cell apoptosis and immune cell activation in the TRAMP-C2 mouse prostate cancer model. Prostate. 2006, 66:831-838.

 Loskog, A., Ninalga, C., and Tötterman, T.H. Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors. Cancer Immunol Immunother 2006, 55:588-597.

 Tötterman, T.H., Loskog, A., and Essand, M. The immunotherapy of prostate and bladder cancer. BJU Int 2005, 96:728-735. Review.

 Loskog, A.S.I., Fransson, M.E., Tötterman, T.H. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res 2005, 11:8816-8821.

 Loskog, A., Ninalga, C., Hedlund, T., Alimohammadi, M., Malmström, P-U., and Tötterman, T.H. Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy. Lab Anim. 2005, 39:384-393.

 Ninalga, C., Loskog, A., Klevenfeldt, M., Essand, M., and Tötterman, T.H. CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer. J Immunother. 2005, 28:20-27.

 Loskog, A., Dzojic, H., Vikman, S., Ninalga, C., Essand, M., Korsgren, O., and Tötterman, T.H. Adenovirus CD40L gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J Immunol. 2004, 172:7200-7205.

Loskog, A., Totterman, T.H., Bohle, A., and Brandau, S., In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154. Cancer Gene Ther. 2002, 9:846-853.

 Loskog, A., Hedlund, T., Wester, K., de la Torre, M., Philipson, L., Malmstrom, P-U., and Totterman, T.H. Human urinary bladder carcinomas express adenovirus attachment and internalization receptors. Gene Ther. 2002. 9:547-553.

 Loskog, A., Bjorkland, A., Brown, M.P., Korsgren, O., Malmstom, P-U., and Totterman, T.H. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol. 2001,166:1093-1097.

Loskog A. CAR T cells – the basics and what’s next? HemaSphere. Educational Updates in Hematology Book. 25th Congress of the European Hematology Association. Virtual Edition. 2020. Review.

Loskog, A. Experimental models for urinary bladder cancer. Int Braz J Urol. 2008. 34. Editorial comment.

Loskog, A., Eliopoulos, A. CD40L-based cancer therapy. New Gene Therapy and Cancer Research. Nova Science Publishers Inc. Editor:Wilma B.Gustafsson. 2008. ISBN: 1-60021-969-1. Expert Commentary. 

Loskog, A. Genetic engineering for cancer immunotherapy. Gene Therapy and Cancer Research Focus. Nova Science Publishers Inc. Editor: Rebecca N. Campbell. 2008. ISBN: 978-1-60021-970-2. Book Chapter.

Loskog, A., and MK Brenner. Reply to “Enhanced CD28 signlaing may be a common mechanism underlying resistance to regulation” by E Wholfert and Clerk RB. Leukemia. 2007, 21:175. Letter to the Editor.

Loskog A. Immunogene Therapy of Bladder Carcinoma: A Preclinical Study. Acta Universitatis Upsaliensis: Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine. ISSN: 0282-7476, Volume 1180, 2002. ISBN:91-554-5402-X. Thesis.

The Lab

Översätt den här sidan